Quality of life and physicians' perception in myelodysplastic syndromes.
Authors:
- Esther Natalie OlivaEOEsther Natalie Oliva
- Carlo FinelliCFCarlo Finelli
- Valeria SantiniVSValeria Santini
- Antonella PoloniAPAntonella Poloni
- Vincenzo LisoVLVincenzo Liso
- Daniela CilloniDCDaniela Cilloni
- Stefana ImperaSIStefana Impera
- Adelmo TerenziATAdelmo Terenzi
- Alessandro LevisALAlessandro Levis
- Agostino CortelezziACAgostino Cortelezzi
- Riccardo GhioRGRiccardo Ghio
- Pellegrino MustoPMPellegrino Musto
- 25 May 2012
- journal article
- Vol. 2 (2) , 136-47
Abstract
To detect factors associated with quality of life (QOL) of patients with myelodysplastic syndrome (MDS) and to compare the MDS patients' self-assessed QOL with that perceived by their physicians. In an observational, non-interventional, prospective, multicentre study, QOL was evaluated in 148 patients with newly diagnosed low- and intermediate-risk IPSS MDS. QOL measures (QOL-E v.2, LASA and EQ-5D) and patient-related candidate determinants of QOL were assessed for up to 18 months. Patients' QOL scores were compared with those obtained by appointed hematologists' assessment and with ECOG performance status (PS). Fatigue was not prevalent at diagnosis, though physical QOL and energy levels were low. Transfusion-dependent patients had worse QOL scores. In multivariate analysis, Hb levels and comorbidities were a major determinant of QOL. Physicians' perception of patients' well-being correlated with patients' QOL. Physicians underestimated the impact of disturbances on patients' QOL, mainly in the MDS-specific components. ECOG PS did not discriminate patients according to QOL status. In conclusion, the association of anemia with QOL is confirmed, while co-morbidities emerge as an independent predictor of QOL in MDS. Fatigue is not a major concern. ECOG PS is not a valuable surrogate of patient's QOL, thus highlighting that physician's judgment of patient's well-being must not substitute patient-reported outcomes. Appropriate questionnaires should be used to assess MDS patients' QOL in order to improve communication and therapeutic choice.Keywords
This publication has 32 references indexed in Scilit:
- Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromesLeukemia Research, 2010
- Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)Blood, 2009
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceBlood, 2008
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELSJournal of Biopharmaceutical Statistics, 2001
- Report of an international working group to standardize response criteria for myelodysplastic syndromes.2000
- On summary measures analysis of the linear mixed effects model for repeated measures when data are not missing completely at randomStatistics in Medicine, 1999
- The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancerCancer, 1999
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987